Th17 cells in MS and experimental autoimmune encephalomyelitis

International MS Journal

Volumn 16, Issue 1, 2009, Pages 12-18

  Hofstetter, Harald H ^a   Gold, R ^b   Hartung, H P ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

Anti cytokine treatment; Autoimmunity; Experimental autoimmune encephalomyelitis; Interleukin 17; Multiple sclerosis; Pertussis toxin; T cell cytokines

Indexed keywords

INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 17F; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; MONOCLONAL ANTIBODY; PERTUSSIS TOXIN; RORIDIN A; STAT3 PROTEIN; STAT6 PROTEIN; TRANSCRIPTION FACTOR C MAF; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL LINEAGE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; EFFECTOR CELL; HELPER CELL; HUMAN; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MICROBIAL ACTIVITY; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH17 CELL; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNOLOGY; TH1 CELL; TH2 CELL;

ANIMALS; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 67649383126     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Gold R, Lühder F. Interleukin-17 - extended features of a key player in multiple sclerosis. Am J Pathol 2008; 172: 8-10.
2. Korn T, Oukka M, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol 2007; 19: 362-371.
3. Dardalhon V, Awasthi A, Kwon H Galileos G, Gao W, Sobel RA et al. IL-4 inhibits TGF-beta induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+IL10 +Foxp3(-) effector T cells. Nat Immunol 2008; 9: 1347-1355.
4. Segal BM, Dwyer BK, Shevach EM. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 1998; 187: 537-546.
5. Becher B, Durell BG, Noelle RJ. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 2002; 110: 493-497.
6. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-748.
7. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240.
8. Zhang GX, Gran B, Yu S, Li J, Siglienti I, Chen X et al. Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. J Immunol 2003; 170: 2153-2160.
9. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278: 1910-1914.
10. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM. IL-12 and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile and response to cytokine inhibition. J Exp Med 2008; 205: 1535-1541.
11. Yao Z, Painter SL, Fanslow WC Ulrich D, Macduff BM, Spriggs MK et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995; 155: 5483-5486.
12. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 2002; 71: 1-8.
13. Broxmeyer HE. Is interleukin 17, an inducible cytokine that stimulates production of other cytokines, merely a redundant player in a sea of other biomolecules? J Exp Med 1996; 183: 2411-2415.
14. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996; 183: 2593-2603.
15. Witowski J, Pawlaczyk K, Breborowicz A et al. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol 2000; 165: 5814-5821.
16. Chabaud M, Page G, Miossec P. Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol 2001; 167: 6015-6020.
17. Chabaud M, Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum 2001; 44: 1293-1303.
18. Katz Y, Nadiv O. Interleukin-17 may have a central role in inflammatory joint diseases as a "fine-tuning" cytokine. Isr Med Assoc J 2000; 2 Suppl: 21-22.
19. Lubberts E, Joosten LA, Chabaud M, van Den Bersselaar L, Oppers B, Coenen-De Roo CJ et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000; 105: 1697-1710.
20. Antonysamy MA, Fanslow WC, Fu F, Li W, Qian S, Troutt AB et al. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 1999; 162: 577-584.
21. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, D'Addio F, Mfarrelj B, Donnarumma M et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008; 205: 3133-3144.
22. Shimada M, Andoh A, Hata K, Tasaki K, Araki Y, Fujiyama Y et al. IL-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators. J Immunol 2002; 168: 861-868.
23. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52: 65-70.
24. Hellings PW, Kasran A, Liu Z, Vandekerckhove P, Wuyts A, Overbergh L et al. Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am J Respir Cell Mol Biol 2003; 28: 42-50.
25. Schnyder-Candrian S, Togbe D, Couillin I, Mercier I, Brombacher F, Quesniaux V et al. Interleukin 17 is a negative regulator of established allergic asthma. J Exp Med 2006; 203: 2715-2725.
26. Chung DR, Chitnis T, Panzo RJ, Kasper DL, Sayegh MH, Tzianabos AO. CD4+ T cells regulate surgical and postinfectious adhesion formation. J Exp Med 2002; 195: 1471-1478.
27. Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43: 2455-2463.
28. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behcet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002; 31: 205-210.
29. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8: 500-508.
30. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999; 5: 101-104.
31. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008; 172: 146-155.
32. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy JM et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132.
33. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-1141.
34. Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB et al. IL-21 initiates an alternative pathway to induce proinflammatory Th17 cells. Nature 2007; 448: 484-487.
35. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006; 441: 235-238.
36. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor beta are essential for the differentiation of interleukin 17 producing human helper T cells. Nat Immunol 2007; 8: 942-949.
37. Gutcher I, Urich E, Wolter K, Prinz M, Becher B. Interleukin 18 independent engagement of interleukin 18 receptor-alpha is required for autoimmune inflammation. Nat Immunol 2006; 7: 946-953.
38. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ et al. The orphan nuclear receptor RORgamma directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126: 1121-1133.
39. Manel N, Unutmaz D, Littman DR. The differentiation of human Th17 cells requires transforming growth factor beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008; 9: 641-649.
40. Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 2007; 282: 9358-9363.
41. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008; 28: 29-39.
42. Chen Q, Yang W, Gupta S, Biswas P, Smith P, Bhagat G et al. IRF-4-binding protein inhibits interleukin 17 and interleukin 21 production by controlling the activity of IRF-4 transcription factor. Immunity 2008; 29: 899-911.
43. Goebels N, Hofstetter H, Schmidt S, Brunner C, Wekerle H, Hohlfeld R. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 2000; 123: 508-518.
44. Hemmer B, Cepok S, Nessler S, Sommer N. Pathogenesis of multiple sclerosis: an update on immunology. Curr Opin Neurol 2002; 15: 227-231.
45. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 1997; 120: 865-916.
46. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007; 8: 913-919.
47. Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, Steinman L et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996; 156: 5-7.
48. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J et al. TNF is a potent antiinflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998; 4: 78-83.
49. Guo B, Chang EY, Cheng G.. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 2008; 118: 1680-1690.
50. Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 2005; 237: 123-130.
51. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006; 177: 566-573.
52. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M et al. Human Th17 lymphocytes promote blood brain disruption and central nervous system inflammation. Nat Med 2007; 204: 161-170.
53. Hofstetter HH, Toyka KV, Tary-Lehmann M, Lehmann PV. Kinetics and organ distribution of IL-17-producing CD4 cells in proteolipid protein 139-151 peptide-induced experimental autoimmune encephalomyelitis of SJL mice. J Immunol 2007; 178: 1372-1378.
54. Bailey SL, Schreiner B, McMahon EJ, Miller SD. CNS myeloid DC presenting endogenous myelin peptides prefentially polarize CD4+ Th-17 cells in relapsing EAE. Nat Immunol 2007; 8: 172-180.
55. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 2005; 11: 335-339.
56. Ifergan I, Kebir H, Bernard M, Wosik K, Dodelet-Devillers A, Cayrol R et al. The blood brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain 2008; 131: 785-799.
57. Ishizu T, Osoegawa M, Mei FJ, Kikuchi H, Tanaka M, Takakur Y et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005; 128: 988-1002.
58. Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen TR et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007; 13: 423-431.
59. Infante-Duarte C, Horton HF, Byrne MC, Kamradt T. Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol 2000; 165: 6107-6115.
60. Giovannoni G, Ebers G. Multiple sclerosis: the environment and causation. Curr Opin Neurol 2007; 20: 261-268.
61. Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, Sayn J et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005; 128: 1667-1676.
62. Derfuss T, Gurkov R, Then Bergh F, Goebels N, Hartmann M, Barz C et al. Intrathecal antibody production against chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response. Brain 2001; 124: 1325-1335.
63. Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2006; 2: 201-211.
64. Lünemann JD, Jelcic I, Roberts S, Lutterotti A, Tackenberg B, Martin et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med 2008; 205: 1763-1773.
65. Correale J, Farez M. Monocyte-derived dendritic cells in multiple sclerosis: the effect of bacterial infection. J Neuroimmunol 2007; 190: 177-189.
66. Hofstetter HH, Shive CL, Forsthuber TG. Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund's adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J Immunol 2002; 169: 117-125.
67. Hofstetter H, Grau C, Buttmann M, Forsthuber TG, Gaupp S, Toyka KV et al. The PLPp-specific T-cell population promoted by pertussis toxin is characterized by high frequencies of IL-17 producing cells. Cytokine 2007; 40: 35-43.
68. Kerfoot SM, Long EM, Hickey MJ, Andonequi G, Lapointe BM, Zanardo RC et al. TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J Immunol 2004; 173: 7070-7077.
69. Hofstetter HH, Luhder F, Toyka KV, Gold R. IL-17 production by thymocytes upon CD3 stimulation and costimulation with microbial factors. Cytokine 2007; 34: 184-197.
70. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008; 223: 87-113.
71. Haak S, Croxford AL, Kreymborg K, Heppner FL, Pouly S, Becher B et al. Il-17A and Il-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest 2008; 119: 61-69.
72. Röhn TA, Jennings GT, Hernandez M, et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol 2006; 36: 2857-2867.
73. Uyttenhove C, Van Snick J. Development of an anti-IL-17A autovaccine prevents experimental autoimmune encephalomyelitis. Eur J Immunol 2006; 36: 2868-2874.
74. Luger D, Silver PB, Tang J, Cua D, Chen Z, Iwakura Y et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 2007; 205: 799-810.
75. Hofstetter HH, Kovalovsky A, Shive CL, Lehmann PV, Forsthuber TG. Neonatal induction of myelin-specific Th1/Th17 immunity does not result in experimental autoimmune encephalomyelitis and can protect against the disease in adulthood. J Neuroimmunol 2008; 187: 20-30.
76. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH et al. Repeated subcutaneous injections of Il-12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008; 7: 796-804.